CRISPR Therapeutics (NASDAQ:CRSP)

Crispr Therapeutics AG (CRSP) is a very professional outfit. Since its de novo in late 2016, the company has always presented itself in the most intelligible, concise, and scrupulous manner. From international conference presentations to downloadable PDF articles hosted on their business website; B2B collaborative ventures to sole experimental endeavors, they have always tried to put their “best foot forward.” Crispr has never folded under political pressure nor baseless market rhetoric. It maintains tight reigns on the promulgation of its progress and intellectual property developments. Crispr seems very “patient-focused” and appears to want to provide permanent, non-repercussive, and precisive treatments for a myriad of serious diseases. If the company reports positive progress from its first American patient, Victoria Gray, the market’s response will be in epic proportion. You cannot use typical fundamental or technical analysis to gauge social sentiment in regards to this company’s valuation or prospective ROI; the company has the potential to make history and disrupt the medical industry as we know it.

The gene-editing market as a whole is in a great position and CRISPR has some strong drug candidates currently being developed.